Disease Monitoring In Multiple Myeloma

被引：1
|
作者：
Hillengass, Jens [1 ]
Martin, Tom [2 ]
Puig, Noemi [3 ]
Paiva, Bruno [4 ]
Usmani, Saad [5 ]
Kumar, Shaji [6 ]
San-Miguel, Jesus [4 ,7 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[3] Dept Hematol Salamanca, Salamanca, Spain
[4] Clin Univ Navarra, CCUN, CIMA, CIBERONC,IDISNA, Pamplona, Spain
[5] Levine Canc Inst Atrium Hlth, Charlotte, NC USA
[6] Mayo Clin, Dept Hematol, Rochester, MN USA
[7] Clin Univ Navarra, Pio 12 Ave 36, Pamplona 31008, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷 / 04期
关键词：
POSITRON-EMISSION-TOMOGRAPHY; MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; IMAGING TECHNIQUES; COMPLETE RESPONSE; SURVIVAL; DIAGNOSIS; THERAPY; CORRELATE; PATTERNS;
D O I：
10.1016/j.clml.2023.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：244 / 248
页数：5
相关论文
共 50 条
  • [41] Interphase fish: A simple method for monitoring minimal residual disease in multiple myeloma.
    Dascalescu, CM
    Garban, F
    Molina, L
    Chauvet, M
    Cousin, F
    Marais, D
    Sotto, JJ
    Leroux, D
    BONE MARROW TRANSPLANTATION, 1998, 21 : S181 - S181
  • [42] Monitoring of residual disease in multiple myeloma (MM) patients using a novel nephelometric assay
    Harding, S.
    Mead, G.
    Drayson, M.
    Bradwell, A. R.
    ANNALS OF ONCOLOGY, 2008, 19 : 238 - 238
  • [43] Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
    Martinez-Lopez, Joaquin
    Wong, Sandy Wai Kuan
    Lopez-Munoz, Nieves
    Bahri, Natasha
    Arora, Shagun
    Kuan, Mikaela
    Dorado, Sara
    Barrio, Santiago
    Chung, Alfred
    Martin, Thomas G.
    Wolf, Jeffrey Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Reliable monitoring of minimal residual disease in multiple myeloma:: how specific is flow cytometry?
    Lioznov, MV
    Cortes-Dericks, L
    Fehse, B
    Zander, AR
    Kröger, N
    BONE MARROW TRANSPLANTATION, 2006, 37 : S146 - S147
  • [45] Individual molecular monitoring of minimal residual disease after autotransplantation in patients with multiple myeloma
    Zherebtsova, V.
    Surin, V.
    Savchenko, V.
    Mendeleeva, L.
    Pokrovskaya, O.
    Turina, N.
    Misurin, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S143 - S143
  • [46] Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients
    Kubiczkova-Besse, Lenka
    Drandi, Daniela
    Sedlarikova, Lenka
    Oliva, Stefania
    Gambella, Manuela
    Omede, Paola
    Adam, Zdenek
    Pour, Ludek
    Sevcikova, Sabina
    Boccadoro, Mario
    Palumbo, Antonio
    Hajek, Roman
    BLOOD, 2014, 124 (21)
  • [47] The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy
    Shires, Karen
    Van Wyk, Teagan
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 132 : 17 - 26
  • [48] Minimal residual disease monitoring in multiple myeloma:: How specific is the flow cytometric analysis?
    Lioznov, M.
    Fehse, B.
    Zander, A.
    Kroeger, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 203 - 203
  • [49] Calorimetric Markers for Detection and Monitoring of Multiple Myeloma
    Krumova, Sashka
    Todinova, Svetla
    Taneva, Stefka G.
    CANCERS, 2022, 14 (16)
  • [50] PROGNOSTIC FACTORS AND MONITORING OF MULTIPLE-MYELOMA
    ESCHARD, JP
    PIGNON, B
    REVUE DE MEDECINE INTERNE, 1992, 13 (04): : 273 - 277
12345